Sandip Patel, MD, presents a case study of a 62-year-old female patient with a PD-L1 expression of 60%, an EGFR exon 20 insertion mutation, and liver lesions, followed by a panel discussion on diagnostic strategies to optimize patient care.
Amivantamab Is Preferred First-Line Pick in EGFR Exon 20 NSCLC
During a Training Academy focused on first-line treatment use in non–small cell lung cancer, panelists discussed a patient case and how they would treat that patient in the setting.